Biomarkers reflecting different facets of Alzheimer's disease

European Journal of Neurology

Volumn 15, Issue 11, 2008, Pages 1143-1144

  Zetterberg, H ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN REGION; CEREBROSPINAL FLUID; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MARKER; EDITORIAL; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; MINI MENTAL STATE EXAMINATION; NERVE FIBER DEGENERATION; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; BRAIN; CEREBROSPINAL FLUID; GLUCOSE; HUMANS; NEUROCHEMISTRY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; TAU PROTEINS;

EID: 53549094400     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2008.02275.x     Document Type: Editorial

References (12)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006 368 : 387 403.
2. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nature Reviews of Neuroscience 2007 8 : 663 672.
3. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Annals of Neurology 2006 59 : 512 519.
4. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiology of Aging 2008 29 : 1456 1465.
5. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006 5 : 228 234.
6. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005 64 : 1294 1297.
7. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neuroscience Letters 2003 352 : 67 69.
8. Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004 9 : 705 710.
9. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003 60 : 1374 1377.
10. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005 64 : 1860 1867.
11. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA: The Journal of the American Medical Association 2001 286 : 2120 2127.
12. Haense C, Buerger K, Kalbe E, et al. CSF total and phosphorylated tau protein, regional glucose metabolism and dementia severity in Alzheimer's disease. European Journal of Neurology 2008 15 : 1155 1162.